937.7500 -9.55 (-1.01%)
NSE Sep 09, 2025 15:31 PM
Volume: 73,236
 

Axis Direct
Q2FY18 revenue declined 10% YoY, while EBITDA margin improved 250 bps YoY at 22.7% led by lower other expenses (-29% YoY) on lower promotion expenses in India business.
Alembic Pharmaceuticals Ltd. is trading below all available SMAs
More from Alembic Pharmaceuticals Ltd.
Recommended